In January 2005, drug product patent protection was reintroduced in India to comply with the agreement on Trade Related Aspects of Intellectual Property Rights. How are the multinational pharmaceutical companies responding to the new policy environment? Is India likely to see monopolisation of the industry and high prices, which was the pattern before 1972 when India had product patent protection? Will the positive features of the post-1972 process patent era be diluted or negated?

German pharmaceutical company Bayer AG has formally lodged a challenge against a landmark Indian ruling that allowed a domestic generic drug-maker to produce a low-cost version of an anti-cancer drug for the Indian market. The appeal was filed on Friday 4 May with India's Intellectual Property Appellate Board.

Liberalisation measures in the pharmaceutical sector have brought about major changes in the industrial licensing policy, import restrictions, foreign direct investment and production controls. It was feared that firms would shift from indigenous production to imports, especially of bulk drugs, and this concern was aggravated with the change in the patent law. This paper finds that these apprehensions have only partly come true. Exports of formulations have grown faster while their imports have not registered any jump, keeping the balance of trade positive.

This paper reviews theoretical and empirical literature that originated predominantly during and after TRIPS, focusing on the influence of changes in patent protection on developing countries. Previous studies identify two channels of gain for developing countries, from strong patent rights. Firstly, the promotion channel whereby, patent rights affect innovativeness of the South and concomitantly its economic growth. Theoretical studies do not give unambiguous hypotheses concerning the influence of patent protection on domestic innovation leaving it for empirical investigation.

In recent years, patenting has been considered one of the major drivers for enhancing national competitiveness and most of the advanced countries have been more actively enforcing patent protection. However, the indicators proposed in previous studies have not been able to deal adequately with the various dimensions of patenting, rather focusing on patent application counts. Therefore, in this research, a comprehensive patent performance indicator is proposed to provide a yardstick by which government policymakers can evaluate the whole process of converting patents into economic assets.

The present study tries to explore the factors that influence the growth, performance, and development of IPR attitude of small and medium-sized enterprises (SMEs) in the manufacturing sector of Punjab. The aim of the present research is to examine the technology management strategies of manufacturing SMEs, primarily on the basis of use-based classification.

The compulsory licence issued to Natco for manufacture of the anti-cancer drug Nexavar is a landmark decision on many grounds – the first one in India since the 2005 amendment to the 1970 Patents Act and the fi rst in the world issued to a private party. There are some ambiguities in the order, but the door is now open for issue of CLs for a number of patented drugs that are not being worked.

The compulsory licence for Nexavar is only the beginning of a new battle over drug prices. (Editorial)

Independent India inherited a structure of landholdings characterised by heavy concentration of cultivable areas in the hands of relatively large absentee landowners, the excessive fragmentation of small landholdings, growing number of landless agricultural workers, and the lack of any generalised system of documentary evidence of landownership or tenancy.